Rebekka Niederer

发表

Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

M. Joerger, V. Walter, N. Klümper, 2022, Science Immunology.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

D. Speiser, B. Ludewig, J. Neefjes, 2019, JAMA oncology.

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

L. Risch, D. Semela, M. Risch, 2021, Journal of Cancer Research and Clinical Oncology.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

R. Dummer, L. Risch, M. Risch, 2019, Journal of immunotherapy.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

R. Dummer, L. Risch, D. Speiser, 2019, Journal of Immunotherapy for Cancer.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

S. Güsewell, C. Ackermann, L. Flatz, 2018, Cancer management and research.

Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy

U. Eriksson, B. Lambrecht, K. McCoy, 2019, Science.

Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibition

R. Dummer, D. Dietrich, C. Garbe, 2021 .

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

D. Schadendorf, S. Ugurel, B. Becher, 2023, Med.

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival

D. Speiser, B. Ludewig, P. Baumgaertner, 2021, Oncoimmunology.